BCG vaccine of 2004 the vaccine is given to about 100 million children per year globally. The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be administered after birth intradermally. BCG vaccination can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease. The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but those conducted elsewhere have shown no protective effect, and efficacy appears
Inoculation theory body to a weakened form of a virus—strong enough to trigger a response (i.e., the production of antibodies), but not so strong as to overwhelm the body's resistance. Attitudinal inoculation works the same way: Expose the receiver to weakened counterarguments, triggering a process of counterargument which confers resistance to later, stronger persuasive messages. This process works like a metaphorical vaccination: the receiver becomes immune to attacking messages that attempt to change their attitudes or beliefs regarding the initial threat. Inoculation theory suggests that if one sends out messages with weak counterarguments, an individual can build immunity to those messages and